October 24, 2019 - "Strong financials driving continued focus on new product opportunities and pipeline progression"
OCTOBER 24, 2019 – With continued strong financials in the quarter, we are on track to deliver a very strong year. The development was mainly driven by Zubsolv® in the US and lower COGS, but also by some adjustment of lower returns and rebates which compensated for the lower volume as a result of some formulary changes in the exclusive plans.
Orexo has a strong history of developing new products approved in markets all over the world. In order to ensure a continued inflow of new improved drugs, the work at the development department in Uppsala, Sweden, has intensified. Filling an unmet need among healthcare professionals and patients is the key in the work of developing new innovative products for treatment of opioid addiction in all phases.
AUGUST 21, 2019 - Orexo will together with its partner GAIA AG develop and commercialize a new digital therapy to increase access and improve treatments of Opioid Use Disorder. Why digital therapies, why now and why together with GAIA? Nikolaj Sørensen, CEO, answers this questions in the latest version of Orexo Our View.